DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
DiaMedica Therapeutics Inc. (DMAC)
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm
Check Earnings Report
Company Research
Source: Business Wire
Conference Call and Webcast August 8 at 8:00 AM Eastern Time / 7:00 AM Central TimeAcute Ischemic Stroke (AIS) Phase 2/3 ReMEDy2 Trial Interim Enrollment (n=144) Targeted for Q1 2025Preeclampsia Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 with Proof-of-Concept Results Targeted for First Half 2025Completed $12 Million Private Placement, Extending Cash Runway Into Q3 2026 MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended June 30, 2024. Management will host a conference call Thursday, August 8, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and second quarter 2024 financial results.ReMEDy2 Phase 2/3 AIS Clinical DevelopmentsProgress continues with site activation activities accelerating. As part of this, DiaMedica has selecte
Show less
Read more
Impact Snapshot
Event Time:
DMAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DMAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DMAC alerts
High impacting DiaMedica Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DMAC
News
- DiaMedica Therapeutics Upcoming Conference ParticipationBusiness Wire
- DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $6.00 price target on the stock.MarketBeat
- DiaMedica Therapeutics Inc. (DMAC) Q2 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year? [Yahoo! Finance]Yahoo! Finance
DMAC
Earnings
- 8/7/24 - Beat
DMAC
Sec Filings
- 8/7/24 - Form 8-K
- 8/7/24 - Form 10-Q
- 7/19/24 - Form EFFECT
- DMAC's page on the SEC website